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Background: Over the last decade two alternative models of donor care have emerged in the United
States: the conventional model, whereby donors are managed at the hospital where brain death occurs, and
the specialized donor care facility (SDCF), in which brain dead donors are transferred to a SDCF for medical
optimization and organ procurement. Despite increasing use of the SDCF model, its cost-effectiveness in
comparison to the conventional model remains unknown.
Methods: We performed an economic evaluation of the SDCF and conventional model of donor care from
the perspective of U.S. transplant centers over a 2-year study period. In this analysis, we utilized nationwide
data from the Scientific Registry of Transplant Recipients and controlled for donor characteristics and
patterns of organ sharing across the nation’s organ procurement organizations (OPOs). Subgroup analysis
was performed to determine the impact of the SDCF model on thoracic organ transplants.
Results: A total of 38,944 organ transplants were performed in the U.S. during the study period from
13,539 donors with an observed total organ cost of $1.36 billion. If every OPO assumed the cost and
effectiveness of the SDCF model, a predicted 39,155 organ transplants (+211) would have been performed
with a predicted total organ cost of $1.26 billion (−$100 million). Subgroup analysis of thoracic organs
revealed that the SDCF model would lead to a predicted 156 additional transplants with a cost saving of
$24.6 million.
Conclusions: The U.S. SDCF model may be a less costly and more effective means of multi-organ donor
management, particularly for thoracic organ donors, compared to the conventional hospital-based model.
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Introduction
The number of deceased organ donors and solid organ
transplants in the United States (U.S.) has consistently risen
in recent years, with approximately 36,500 transplants from
10,700 deceased donors performed in 2018 alone (1). The
current method of organ allocation allows donors to be
matched with appropriate recipients nationwide, requiring
substantial coordination and typically necessitating travel
by several transplant teams for each donor (2). Donor
management, organ allocation, and procurement operations
are coordinated by 58 federally mandated, non-profit organ
procurement organizations (OPOs), each managing donors
within its respective geographic service area. Traditionally,
this requires a donor’s OPO to communicate extensively
with multiple transplant centers and coordinate care with
the referring hospital where the donor resides. In an effort
to optimize the efficiency of this process and potentially
reduce costs, our local OPO, Mid-America Transplant
(MOMA), built the country’s first freestanding specialized
donor care facility (SDCF) in 2001. In this model, donation
after brain death donors are transferred from the referring
hospital to the SDCF for medical optimization while
organ allocation is coordinated with transplant centers
(Figure 1). The SDCF maintains its own in-house critical
care unit, laboratory, radiographic equipment (i.e., CT
scanner), and procurement operating rooms, resulting in a
streamlined process of donor care. After the donor workup
is complete and organs have been accepted by transplant
centers, procurement teams travel to the SDCF for organ
procurement.
By 2011, 93% of all procurements from MOMA were
being conducted at the SDCF, which was associated with
a reduction in surgeon air travel and overall cost of donor
management (3,4). Furthermore, organ procurement from
MOMA’s SDCF has been associated with an increase in
organ yield per donor (4,5). At least 12 other OPOs in the
U.S. have since either adopted the SDCF model or are in
the process of doing so. However, a national comparison
of the SDCF model with the conventional model of donor
management while controlling for donor characteristics
has not been performed. Furthermore, a nationwide
economic evaluation from the perspective of U.S. transplant
centers has also not been previously conducted. This holds
tremendous importance with regards to donor management
policy given the limited resources and wide variability of
donor characteristics and organ acquisition costs. Not
only is this important for transplant centers in the U.S.,
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it is likely that the SDCF model of care has important
characteristics that can be successfully adapted to support
organ transplantation, particularly for thoracic organs,
worldwide.
Given the sustained increase in organ donors over
the last decade and the high cost associated with organ
acquisition, it is critically important to compare the various
models of donor care. To address this gap, we conducted
an economic evaluation of the SDCF model compared to
the conventional model of donor care in the U.S. from the
perspective of transplant centers. We present the following
article in accordance with the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS)
reporting checklist (available at http://dx.doi.org/10.21037/
jtd-20-1575).
Methods
In this analysis we conducted an economic evaluation from
a transplant center’s perspective to compare the SDCF
model with the conventional model of hospital-based donor
care. To accomplish this, we compare the observed (actual)
cost and effectiveness of the nation’s OPOs during the
study period with that of a predicted scenario in which all
OPOs adopted the SDCF model of care. We chose to use
nationwide data from the Scientific Registry of Transplant
Recipients (SRTR) (6) to measure effectiveness, as this data
is rigorously adjusted for individual donor characteristics
and allows for accurate comparisons of performance among
our country’s OPOs. We adjusted for patterns of organ
sharing across the nation’s OPOs which vary across different
regions of the country.
Organ acquisition charge (OAC) was used to compute
organ costs. When a transplant center (e.g., Barnes-Jewish
Hospital) accepts an organ for transplantation, the OAC is
paid by that center to the respective OPO (e.g., MOMA)
and ultimately reimbursed by private insurance companies
or the government via the Center for Medicare & Medicaid
Services. The OAC is used by OPOs to fund the cost of
managing an organ donor in the hospital, coordinating
the donation process, reimbursing hospitals for operating
room charges, and in the case of an SDCF, transportation
and management of the donor at the facility. Therefore, the
OAC of an organ represents the unit cost of that organ to
a transplant center. At MOMA, the OAC for a given organ
does not change based on donation after brain death or
cardiac death status.
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Brain dead potential multiorgan
donor

Conventional model
• Donor care at hospital where brain
death occurs
• No transportation required
• Managed by donor hospital ICU
team with OPO staff assisting

SDCF model
• Donor transported to SDCF
• Donor directed care to optimize
organ yield

Procuring surgical teams travel to
hospital

Procuring surgical teams travel to
SDCF

Multiorgan procurement
operation

Figure 1 Illustration of the specialized donor care facility (SDCF) model of donor care. In the conventional model of hospital-based donor
care, a referring hospital notifies an organ procurement organization (OPO) of a potential organ donor, and the OPO then coordinates
donor care and workup between the referring hospital, OPO, and transplant centers. In the SDCF model, the OPO transports brain
dead donors to the SDCF for workup, medical optimization, recipient matching, and coordination of procurement, thereby streamlining
donor care.

Cost savings in the absence of comparable or improved
effectiveness would be undesirable in any new model of
care. Therefore, effectiveness was measured using each
OPO’s observed and predicted number of transplants
performed during the study period for heart, lung, liver,
kidney, and pancreas. Single and double lung transplants
were counted as one organ, while kidney transplants were
counted separately. Due to their rarity, small intestine
transplants were excluded from the analyses (Figure S1).
Both donation after cardiac death and brain-dead donors
were included in this analysis.
Data
Effectiveness
The number of organ donors and the observed and
expected number of transplants for each OPO was obtained
from OPO-specific reports from the SRTR (Supplementary
material, A). The expected number of transplants for each
organ is derived from a statistical model that adjusts for
38 donor characteristics, such as age, cause of death, and
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medical co-morbidities, and is published by the SRTR (6)
(see Table S1). The organ-specific observed-to-expected
ratio (O:E) for each OPO represents the observed number
of transplants for a given organ divided by the expected
number of transplants for that organ. Local organ
transplants were defined as those donated to a transplant
center within the OPO’s donation service area (DSA), while
export organ transplants were those donated outside of an
OPO’s DSA (Figure 2). It is important to account for the
local and export organ transplants in each OPO as the OAC
for export organs is usually higher due to travel costs and
greater logistical burden. January 1, 2013 to December 31,
2014 was chosen as the study period, as this was the most
recent period for which all required data were available.
Cost
The local and export organ-specific OACs for each OPO
were obtained from OPO-reported data from the year
2014 (presented at the Association of Organ Procurement
Organizations annual meeting). The OPO-specific OACs
have not been reported publicly since 2014.
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Midwest donation
service area

Northeast donation
service area

Transplant
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Transplant
center
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Local

Figure 2 Illustration of local and export donations from two organ procurement organizations (OPOs). Each of the 58 OPOs in the U.S.
manages a donation service area (DSA) (represented by black lines), which collectively encompass all 50 states. Using organ allocation
algorithms and current policies, an OPO matches donor organs to recipients both inside its DSA, termed “local” transplants (blue lines),
and outside its service area, termed “export” transplants (red lines). Export donations generally confer a higher OAC due to increased
administrative burden and travel costs. These DSA boundaries are for illustrative purposes only and do not represent actual DSA boundaries.

Observed organ transplants

Thus, the liver-specific observed total costs for OPO A =
($30,000×203) + ($36,000×104) = $9,834,000.
We then computed organ-specific observed average
OAC nationwide by averaging observed organ-specific
OACs from each OPO. Organ-specific observed total costs
nationwide were derived from the sum of observed organspecific total costs from each OPO.

For each OPO, the number of organ-specific observed
transplants were obtained from the SRTR reports (6).
Organ-specific observed total transplants nationwide were
obtained by summing observed transplants from each OPO
(Supplementary material, B).
Observed costs
For each OPO, organ-specific local and export OACs were
used to compute the organ-specific observed average OAC
(a weighted average of local and export OACs with weights
determined by the number of local and export organs),
and observed total costs (sum of local and export costs)
(Supplementary material, C).
As an example, during the study period OPO A
(conventional model) observed 307 liver transplants,
including 203 local transplants with liver OAC = $30,000
and 104 export transplants with liver OAC = $36,000.

© Journal of Thoracic Disease. All rights reserved.

Predicted transplants assuming nationwide adoption of the
SDCF model
We assumed a scenario in which all OPOs in the U.S.
adopted the SDCF model and achieved the same
effectiveness. Data from MOMA’s performance was used
to inform effectiveness, as this was the nation’s only fully
functioning SDCF in the year prior to the study period.
Under such a scenario, we assume that each OPO has the
same O:E as that of the SDCF while retaining its own
capacity (E). Therefore, the organ-specific predicted total
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transplants was calculated by multiplying the organ-specific
expected transplants for each OPO by the SDCF’s O:E
ratio for that organ.
As an example, OPO A (conventional model) observed
70 lung transplants from 367 donors during the study
period, while 69.4 lung transplants were expected based on
the SRTR’s statistical model (6). During the same period,
the SDCF’s lung O:E was 1.18. Therefore, the predicted
number of lung transplants from OPO A based on the
SDCF’s performance =69.4×1.18=81.9. The organ-specific
predicted total transplants nationwide were calculated by
summing the predicted transplants for each OPO across all
OPOs (Supplementary material, D).

effectiveness (mean overall predicted total transplants
from the bootstraps and overall observed total transplants)
against cost (mean overall predicted total cost from the
bootstraps and overall observed total cost). All analyses were
conducted using Microsoft Excel, version 16 (Albuquerque,
NM, USA).
Results
Nationwide observed cost and effectiveness

Predicted costs assuming nationwide adoption of the SDCF
model
Under the aforementioned scenario in which all OPOs in
the U.S. adopted the SDCF model, the observed OAC of
the SDCF was assumed to be the organ-specific predicted
average OAC for all OPOs (Supplementary material, E).
The overall predicted average OAC was obtained by
averaging the organ-specific predicted average OACs for
the studied organs.
As an example, during the study period OPO A
(conventional model) was expected to perform 304 liver
transplants with local and export proportions of 0.66
and 0.34, respectively. The SDCF’s OAC for local liver
transplants was $26,000, OAC for export liver transplants
was $38,000, and O:E ratio of the SDCF model for liver
was 1.06. As described above, the predicted number of
liver transplants for OPO A =304×1.06=322. Thus, the
liver-specific predicted total costs from OPO A =322 ×
($26,000×0.66 + $38,000×0.34) = $9,685,760.
Statistical and economic analysis
The primary measure of benefit was the difference in total
transplants and cost between the observed and predicted
scenarios. The secondary measure of benefit was the
difference in organ-specific transplants and cost between
the two scenarios. All OPOs lacking complete cost or
effectiveness data during the study period were excluded
from the analysis. Descriptive statistics were computed.
Bootstraps were performed to resample OPOs 1,000 times
with replacement when computing the predicted transplants
and costs to obtain means and 95% confidence intervals
(CIs). Cost-effectiveness plane was plotted to demonstrate

© Journal of Thoracic Disease. All rights reserved.

During the study period MOMA was the only established
SDCF in the country which was transferring nearly all of
its donors to the freestanding facility. Thirteen OPOs did
not have complete data available and were excluded from
the analysis (Figure S1). Nationwide, 38,944 transplants
of the 5 organs of interest (heart, kidney, liver, lung, and
pancreas) were observed from 13,539 individual donors (289
transplants per 100 donors) over the 2-year study period
(Table 1).
The nationwide observed total costs paid by transplant
centers to the OPOs was $1.36 billion (Table 2). The
observed average OAC was $37,599 per organ. Lungs had
the highest observed average OAC ($46,276), followed by
heart ($37,743).
Nationwide predicted costs and effectiveness presuming
SDCF model of care
Assuming nationwide adoption of the SDCF model, the
overall predicted total transplants nationwide would have
been 39,155 (95% CI: 38,977–39,334), an increase of 211
transplants compared to the observed effectiveness (Table 1).
The overall predicted total organ cost nationwide was $1.26
billion (95% CI: $1.26–1.27 billion), a decrease of $100
million compared to the overall observed total organ costs
nationwide. The predicted average OAC for every organ
was lower compared to the observed average OAC based on
the conventional model of care (overall mean $32,127 vs.
$37,599) (Table 2).
Evaluation of the cost and effectiveness of nationwide
adoption of the SDCF model
We evaluated the cost and effectiveness of nationwide
adoption of the SDCF model by comparing the overall
total transplants and organ costs between the observed and
predicted scenarios. The predicted scenario dominated
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Table 1 Observed and predicted effectiveness of organ transplantation
Number of transplants

HR

KI

LI

LU

PA

Overall

Observed total transplants
nationwide

4,208

19,982

10,167

2,937

1,650

38,944

Observed transplants per
100 donors nationwide

31

149

76

21

12

289

Predicted total transplants
nationwide (95% CI)

3,914
(3,895, 3,932)

3,387
(3,369, 3,404)

1,656
(1,648, 1,663)

39,155
(38,977, 39,334)

25 [25, 25]

13 [12, 13]

290 [290, 290]

Predicted transplants per
100 donors nationwide [95% CI]

29 [29, 29]

19,530
10,670
(19,444, 19,615) (10,621, 10,719)
145 [145, 145]

79 [79, 79]

Observed transplants refers to the actual number of organ transplants in total and per 100 donors during the study period. Predicted
transplants refers to the number of organ transplants in total and per 100 donors based on the SDCF model and includes 95% confidence
intervals (CIs). 95% confidence intervals were generated by the bootstrapped results. HR, heart; KI, kidney; LI, liver; LU, lung; PA,
pancreas; AVG, national average; SDCF, specialized donor care facility.

Table 2 Observed and predicted cost of organ transplantation
Cost

HR

KI

LI

LU

PA

Overall

Observed total cost ($)

156,882,745

646,509,241

366,444,371

132,045,589

59,229,109

1,361,111,055

Predicted total cost
(95% CI) ($)

126,630,733
(126,031,400,
127,230,066)

622,847,899
(620,086,201,
625,609,598)

320,790,524
(319,346,831,
322,234,218)

137,715,189
(137,040,238,
138,390,140)

53,464,409
(53,219,362,
53,709,456)

1,261,448,754
(1,255,724,031,
1,267,173,477)

Observed average OAC ($)

37,743

32,053

36,299

46,276

35,622

37,599

Predicted average OAC ($)

30,407

32,000

28,862

36,576

32,792

32,127

Observed total cost and OAC refer to the actual total cost and average OAC during the study period. Predicted total cost and OAC refer
to the total cost, including 95% confidence intervals (CIs), and average OAC based on the SDCF model. OACs are given as the weighted
national average. 95% confidence intervals were generated by the bootstrapped results. All costs are in 2014 U.S. dollars. HR, heart; KI,
kidney; LI, liver; LU, lung; PA, pancreas; OAC, organ acquisition charge; SDCF, specialized donor care facility.

the observed scenario by being less costly (i.e., nationwide
predicted total costs − observed total costs = −$100 million;
last column in Table 2) and more effective (i.e., nationwide
predicted transplants − observed transplants = +211
transplants; last column in Table 1) (Figure 3A).
Among the 211 additional transplants that were predicted
with adoption of the SDCF model, 156 (74%) of these were
from thoracic organs (heart and lungs). Subgroup analysis
of thoracic organs alone demonstrated that the predicted
scenario dominated the observed scenario by leading to an
increase in thoracic transplants (+156) at a lower total organ
cost (−$24.6 million) (Figure 3B).
Discussion
We have performed an economic evaluation comparing
the SDCF model of donor care to the conventional model
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of hospital-based care in the U.S. while accounting for
regional variations in donor characteristics and patterns
of organ sharing across the country’s OPOs. Our results
show that the SDCF model may be a cost-effective means
of donor management in the U.S. from a transplant
center’s perspective, which may lead to an increase in
thoracic organ transplants at a lower per transplant cost.
While the predicted total number of organ transplants
was slightly higher than the observed number of organ
transplants, the predominant reason for the SDCF model’s
cost-effectiveness is a substantially lowered predicted
organ cost. With the changing landscape of organ donor
management and the consistent increase in organ donors
in recent years (7), these findings have important and farreaching implications for health care economics and donor
management policy (8), both at a national and international
level.
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A

B
1.35

300
Total cost (millions of $)

Total cost (billions of $)

1.40
Observed

1.30
Predicted

1.25
1.20
38500

Observed
280
Predicted

260

240
39000

  39500

40000

7000

Total transplants

  7200

7400

Total transplants

Figure 3 Observed and predicted overall cost and effectiveness of the specialized donor care facility (SDCF) model of care compared to the
conventional model. Overall total costs nationwide are shown in billions and millions of U.S. dollars for all organs (A) and thoracic organs
(B), respectively. Overall total transplants nationwide refer to the sum of all transplants done by the 45 organ procurement organizations
(OPOs) in this study for the 5 organs of interest (heart, liver, lung, kidney, pancreas). Thoracic organs represent the sum of lung and heart
transplants alone. The observed data point is based on the actual outcomes during the study period, while the predicted data point is based
on nationwide adoption of the SDCF model during the study period.

The reasons for cost savings using the SDCF model
are multifactorial but largely appear to be a result of lower
overhead costs and greater efficiency in donor management.
In the conventional model of donor care, all procedures
and hospital-based workup add to the overall cost of donor
management, which is paid for by the donor’s OPO. For
example, if a donor needs a CT scan and bronchoscopy
while at the referring hospital, both studies will confer
additional cost to the OPO, which will ultimately be passed
on to transplant centers through the OAC. Conversely,
in the SDCF model the diagnostic workup is centralized,
with radiographic studies, diagnostic testing, and laboratory
analysis being performed at the SDCF via OPO-owned
resources. Similarly, the SDCF model is likely to result
in lower professional fees as well. A donor requiring
bronchoscopy and dialysis in the conventional setting
will be managed by a pulmonologist and a nephrologist,
while in the SDCF model, a critical care physician or
other personnel, who are extremely familiar with donor
management and employed by the OPO, will provide
these services. Donor care is a complex process that most
hospitals are unfamiliar with. In this regard, the SDCF can
be regarded as a “high-volume” center that performs these
complex tasks frequently and efficiently. By co-locating
services, such as radiographic machines, diagnostic testing
equipment, intensive care units, and procurement operating
rooms, the SDCF is able to simplify the donor management
process. Despite recent changes in organ allocation policy
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in the U.S., the benefits of the SDCF are likely to be
maintained due to inherent efficiencies of the model that
facilitates a streamlined organ donor management and
recovery process and lowers the cost of donor care.
The SDCF model can reliably institute specific
algorithms to increase organ yield, which may be one factor
contributing to the increase in effectiveness. A prior study
by our group demonstrated that a lung focused resuscitation
protocol implemented by a SDCF led to increased organ
yield (5). Similarly, a previous study from our institution
demonstrated that transferring a donor to a SDCF
increased the overall organ yield (3.43 vs. 2.69 organs per
donor, P<0.0001) and was associated with a lower mean
donor recovery cost ($16,153 vs. $33,161, P<0.0001) (4).
The transfer process itself appears to be relatively quick,
with a median time from family consent to transfer of
8.6 hours, and has been associated with a very high family
satisfaction (4). We have also found that procurement from
the SDCF, rather than a referring hospital, was correlated
with higher likelihood of daytime, rather than after-hours
transplants (9). Therefore, it appears that transfer to a
SDCF is efficient from a number of perspectives, including
that of surgeons and donor families, and may confer other
advantages not examined in this study. It remains to be
seen if the benefits of a SDCF appreciated in the U.S. will
be seen in other countries. To our knowledge no similar
facilities exist outside of the U.S. However, we strongly
anticipate that the fundamental efficacy of the SDCF model
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can be replicated not only in the U.S., but internationally.
Since the SDCF model requires a freestanding organ
recovery center, the cost of initiating this model is worthy
of discussion. A prior study of our local SDCF estimated
the startup cost to be $5.34 million (construction, medical
equipment, etc.) (4). In the current study we found a cost
savings of $100 million for 45 OPOs using the SDCF
model, resulting in approximately $2.2 million in savings
per OPO during the study period. Therefore, one could
envision that OPOs could use the differences in cost of
donor management to offset startup costs. Our results also
suggest that implementation of the SDCF model may be in
the best interest of transplant centers as well, and they may
be incentivized to fund a portion of a SDCF’s startup cost.
A few critical elements are required for the SDCF
model to succeed and these should be carefully considered
before another country or other U.S. OPOs adopt this
model. First, the donor volume should be high enough that
the cumulative OACs can finance the costs of running a
SDCF. The leadership at our local OPO has estimated this
number to be around 100 donors per year, which would
have encompassed 38 of the 58 OPOs during our study
period. It appears that the SDCF model functions optimally
when built geographically close to high volume transplant
centers, as this has been shown to reduce travel time and
the number of “fly outs” by the procurement team in both
real (3) and hypothetical (10) models of donor management.
In the setting of new U.S. organ allocation policies, which
have been shown to increase air travel (8), it may be ideal to
locate new SDCFs close to airports.
Our results must be interpreted with some limitations
in mind. We have conducted an economic evaluation
from the perspective of U.S. transplant centers, which
is only one of several perspectives that one could take
when conducting such an analysis. The perspective of the
payer (i.e., private insurance companies or the Center for
Medicare & Medicaid Services), the referring hospital, and
donor families was not examined in this analysis. The study
period represents the most recent era for which all required
U.S. cost data were available, and costs may have changed
since then. Notably, while all 58 OPOs in the country
are not for profit organizations, various OPOs are likely
to have different margins of “profit” for different organs;
unfortunately, this information is unavailable and unlikely
to become available in the public domain. Hence, we used
publicly available OACs as our best proxy of true cost of
organs.
Given that transferring a donor to a SDCF generates
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an additional cost to the OPO, which will ultimately be
passed on to transplant centers through the OAC, the
geographic location of a SDCF may influence overhead
cost. Furthermore, one limitation of this study is that
our use of the O:E ratio as a measure of performance is
nuanced and potentially reflective of the performance
of accepting transplant centers in close proximity to the
OPO. For example, our local OPO (MOMA) transfers
31% of donors to the SDCF by plane and the remainder
by ground, which may not be representative of other
OPOs (4); this is particularly relevant for countries that
share organs across international lines, a model adopted in
Europe (11). Furthermore, given that no other OPOs had
fully implemented a SDCF during the study period, our
results are extrapolated from the performance of a single
SDCF, which may have overstated or understated certain
aspects of cost or effectiveness. However, with four other
OPOs having adopted the SDCF model since 2014 and
seven others in the process of doing so, it appears that the
U.S. healthcare system is already aligning itself with the
most cost-effective model of donor care. As more SDCFs
are implemented across the country and their data becomes
available, studies will be undertaken which examine the
performance of multiple centers using this model.
In conclusion, we have found that from a U.S. transplant
center’s perspective the SDCF is a less costly, more
effective model of donor care, particularly with regard
to thoracic organs, when compared to the conventional
model of hospital-based donor care. Our study predicts
that nationwide adoption of the SDCF would result
in a slightly higher number of organ transplants while
substantially lowering the cost of organ acquisition. We
urge international policymakers, payers, and transplant
centers to consider incentives that facilitate a transition to
the SDCF model of donor care.
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Abbreviations









y: organ of interest (heart, liver, lung, kidney, or pancreas);
OBS: observed;
EXP: expected;
PRED: predicted;
Σ: total;
x: average;
TXP: transplants;
TXP/100: transplants per 100 donors.

A. Data
The following data were obtained from the SRTR reports (5): organ-specific observed transplants (yOBS TXP), number of
organ donors, local and export number of transplants (yTXPlocal, yTXPexport), and organ-specific observed-to-expected ratios
(O:E) for each OPO. The local and export organ-specific OACs for each OPO was obtained from OPO-reported data from
the year 2014.
B. Observed organ transplants
Organ-specific observed total transplants nationwide (yOBS Σ TXP nationwide) was obtained by summing yOBS ΣTXP for
OPOi, i=1,...,n over all OPOs.
n

yOBS ∑ TXP nationwide =
∑ yOBS TXP for OPOi

[1]

i =1

where i is the index for OPO, and n is the number of all OPOs.
Overall observed total transplants nationwide was computed by summing yOBS ΣTXP nationwide over all interested
organs:

∑ y yOBS ∑ TXP nationwide
overall OBS ∑ TXP nationwide =
∑

[2]

y

where y is organ of interest: heart, liver, lung, kidney, or pancreas.
The organ-specific observed transplants per 100 donors for OPOi is obtained by
=
yOBS TXP /100 for OPOi

yOBS TXP for OPOi
×100.
number of organ donors for OPOi

[3]

Organ-specific observed total transplants nationwide per 100 donors is computed as follows:
n

yOBS TXP /100 nationwide = ∑ yOBS ?TXP /100 for OPOi

[4]

i =1

Overall observed total transplants nationwide per 100 donors was computed by summing yOBS ΣTXP/100 nationwide over
all interested organs:

∑ y yOBS ∑ TXP /100 nationwide
overall OBS ∑ TXP /100 nationwide =
∑

y

[5]

C. Observed costs
Organ-specific OAC for OPOi was obtained by the weighted average of local yOAC and export yOAC, where weights were
determined by the number of local transplants and the number of export transplants:

yTXPi local
yTXPi export
export
OAC
+
y
×
i
yTXPi local + yTXPi export
yTXPi local + yTXPi export

yOAC for OPOi =yOAClocal
×
i

[6]

Organ-specific observed average OAC was computed by:

∑
yOBS x OAC =

n
i =1

yOACi

[7]

n

Overall observed average OAC was computed by:

overall OBS x OAC =

∑

y

yOBS x OAC

∑

[8]

y

Organ-specific observed cost (yOBS Σcost) for each OPO was computed by multiplying the local OAC (yOAClocal) by
the number of local y transplants and adding this to the product of export OAC (yOACExport) and the number of export y
transplants.
yOBS costs for OPOi = yOAClocal
× yTXPi local + yOACiexport × yTXPi export
i

[9]

Organ-specific observed total costs nationwide were then obtained by
n

yOBS ∑ costs nationwide =
∑yOBS costs for OPOi
i =1

[10]

Overall observed total costs nationwide were obtained by summing organ-specific observed total costs nationwide over all
interested organs, as follows:

overall OBS ∑ costs nationwide =
∑yOBS ∑ costs nationwide
y

[11]

D. Predicted organ transplants assuming nationwide adoption of the SDCF model
O
y
Assuming nationwide adoption of the SDCF model,  E  SDCF will be used as the effectiveness of each OPO, while organspecific expected total transplants for each OPO remains the same. The organ-specific predicted transplants (yPRED ΣTXP)
for each OPO was calculated by multiplying the organ-specific expected total transplants (yEXP ΣTXP) for each OPO by the

O
SDCF’s O:E ratio for that organ [ y  
].
 E  SDCF
O
yPREDTXP
=
for OPOi yEXPTXP for OPOi × y  
 E  SDCF

[12]

Organ-specific predicted total transplants nationwide (yPRED ΣTXP nationwide) was computed by summing yPRED
ΣTXP for each OPO over all OPOs.
n

yPRED ∑ TXP nationwide =
∑yPRED TXP for OPOi
i =1

[13]

Overall predicted total transplants nationwide was calculated by summing yPRED ΣTXP nationwide over all interested
organs, as follows:

overall PRED ∑ TXP nationwide =
∑yPRED ∑ TXP nationwide
y

[14]

Organ-specific predicted transplants per 100 donors for each OPO was obtained by
yPREDTXP for OPOi
× 100
number of organ donors for OPOi

=
yPREDTXP /100 for OPOi

[15]

The organ-specific predicted total transplants nationwide per 100 donors (yPRED TXP/100 nationwide) was computed
by.
n

yPRED ∑ TXP /100 nationwide =
∑yPRED TXP /100 for OPOi

[16]

i =1

Overall predicted total transplants nationwide per 100 donors was calculated by summing yPRED TXP/100 nationwide
over all interested organs, as follows:

overall PRED ∑ TXP /100 nationwide =∑
∑yPRED TXP /100 nationwide
y

erall PRED ∑ TXP /100 nationwide =∑
∑yPRED TXP /100 nationwide

[17]

y

E. Predicted costs assuming nationwide adoption of the SDCF model
Organ-specific predicted average OAC was computed by:

yPRED x OAC =

∑

n
i =1

yPRED OAC for OPOi
n

[18]

where

yPRED OAC for OPOi = yOAClocal
SDCF ×

local
export
yTXPSDCF
yTXPSDCF
export
OAC
+
y
×
SDCF
local
export
local
export
yTXPSDCF
+ yTXPSDCF
yTXPSDCF
+ yTXPSDCF

[19]

Therefore, yPRED x OAC = yPRED x OACSDCF .
Overall predicted average OAC for each OPO was computed by taking the average of yPRED x OAC over all interested
organs.

overall PRED x OAC =

∑

y

yPRED x OAC

∑

[20]

y

Organ-specific predicted costs for each OPO were obtained by:

yPRED
=
costs for OPOi yPREDTXP for OPOi × yPRED OAC for OPOi

[21]

Organ-specific predicted total costs nationwide were then computed by:
n

yPRED ∑ costs nationwide =
∑yPRED costs for OPOi
i =1

[22]

Figure S1 Flow diagram of OPOs and transplants included in the study. Of the 58 OPOs in the U.S., 45 had complete cost and effectiveness
data for the 2-year study period. Due to their rarity, small bowel transplants were excluded from the study. Single and double lung
transplants are counted as one organ, while kidney transplants are counted separately. Data taken from SRTR reports (5). OPOs, organ
procurement organizations; SRTR, Scientific Registry of Transplant Recipients.

Table S1 Predictors of organ yield
Age effect for brain dead donors
Blood type
Body mass index
Cardiac arrest after brain death
Cause of death
Circumstance of death
Clinical infection: blood
Clinical infection: lung
Clinical infection: other
Clinical infection: urine
Controlled DCD donor
Current cigarette use
Current cocaine use
Current other drug use
Ejection fraction (percent)
Ethnicity
Gender
Heavy alcohol use
Height
History of cancer
History of cocaine use
History of diabetes
History of hypertension
History of insulin dependence
History of other drug use
Intercept
Mechanism of death
More than 20 pack years
PHS increased infectious risk
pO2/FiO2 ratio
pO2
Previous MI
Protein in urine
Race
Terminal serum creatinine
Weight
History of any diabetes
Recovered outside the contiguous 48 states?
Donor characteristics used by the Scientific Registry of
Transplant Recipients to determine expected organ yield for
each OPO based on the number of potential organ donors.
OPO, organ procurement organization; DCD, donation after
cardiac death; PHS, U.S. Public Health Service.

